Imugene Crown Jewel - Phase 1 onCARlytics trial doses first...

Imugene Crown Jewel - Phase 1 onCARlytics trial doses first patient in Intravenous (IV) combination arm.
Dosed the first patient with cholangiocarcinoma, or bile tract cancer, in the intravenous (IV) infusion combination arm of the trial at City of Hope on 24 June 2024.

Dose Escalation Combination Phase:
CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28-day cycle.
Blinatumomab (Blincyto) will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.

IMO, today, this patient would have received 4 doses of CF33-CD19, followed by 3 (7-day continuous infusions of Blincyto), and from tomorrow patient due an additional 7-day infusion of Blincyto.

Note: In February 2024, the first patient with bile tract cancer was dosed in the IV monotherapy arm of
the trial at City of Hope.
CF33-CD19 IV Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.

Note: 26 October 2023 first patient dosed - Ovarian cancer at City of Hope.

Yuman Fong and Leslie Chong are excited with what they are seeing and achieving with the science.to date.

Regards.